Phototherapy for atopic eczema

Musters, Annelie H; Mashayekhi, Soudeh; Harvey, Jane; Axon, Emma; Flohr, Carsten; Drucker, Aaron M.; Gerbens, L. A. A.; Ferguson, John; Ibbotson, Sally H.; Dawe, Robert S.; Garritsen, Floor M.; Brouwer, Marijke Willemijn Dorothée; Limpens, Jacqueline; Prescott, Laura; Boyle, Robert; Spuls, Phyllis I.

doi:10.1002/14651858.cd013870.pub2

Cited by 21 publications

(20 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our previous studies [3][4][5] found that the most common first line, topical non-medicated therapy for adults and children with moderate to severe AD was phototherapy. In these surveys, NBUVB was the most frequently prescribed, then followed by PUVA and finally UVA1 was the least frequently prescribed (mainly due to lack of access).…”

Section: Discussionmentioning

confidence: 99%

“…European (EU) guidelines exist to guide us in our use of phototherapies for AD 1,2 . In our previous survey of AD therapies 3–5 phototherapy was found to be the most frequently initiated therapy after topical treatment for moderate‐to‐severe AD among European dermatologists, in particular NBUVB. However, evidence for its efficacy, impact on quality of life, cost‐effectiveness and short‐ and long‐term safety is weak with respect to real‐life usage, as evidenced by a recent Cochrane review 6 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phototherapy for atopic dermatitis: A survey of European practice

Steyn,

Gerbens,

Spuls

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundPhototherapy is used to treat atopic dermatitis (AD). Evidence for its efficacy, impact on quality of life, cost‐effectiveness and short‐ and long‐term safety with real‐life usage is weak.ObjectivesWe established a taskforce to examine how phototherapy is currently being used as a treatment for AD across the United Kingdom and Europe to inform our understanding and guide future research into management of patients with AD using UV‐based phototherapies.MethodsAn anonymous electronic multiple‐response survey exploring phototherapy prescribing practices and experience of phototherapy modalities was developed by the study authors and sent to members of phototherapy networks from the United Kingdom and Europe. Responses were received between February and July 2021.ResultsAbout 144 respondents from 27 European countries completed the survey. NBUVB was the most widely used [n = 138 (96%)]. Home‐based NBUVB was available in 8/27 countries (25/144 respondents, 17%). Oral psoralen‐UVA (PUVA) was more widely available than bath PUVA (n = 106, 74% vs. n = 60, 42%) and used mainly in adult patients. 49/144 (34%) of respondents had access to UVA1. Phototherapy would be considered instead of systemic treatment in 96% of adults and 82% of children for NBUVB, versus 40% of adults and 3% of children for PUVA. Starting doses, standard dosing increments, length of treatment courses, lifetime limits for treatments and thresholds for performing annual skin assessments varied between responders.ConclusionsNBUVB was the most widely used phototherapy for AD in adult and paediatric patients, while PUVA and UVA1 were less used. Prescribing practices varied considerably, highlighting the lack of consensus practice in many different aspects of phototherapy for the treatment of AD in children and adults. This indicates that further studies are required to determine optimal phototherapeutic regimens for AD and informs our understanding of parameters that should be included in future high‐quality randomized controlled trials (RCT) of phototherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Phototherapy for atopic dermatitis: A survey of European practice

Steyn,

Gerbens,

Spuls

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Kolejnym rzutem w leczeniu jest fototerapia. Wykorzystywane jest światło UVA, UVB oraz psolareny w połączeniu z UVA (PUVA) [21]. Nowymi lekami dopuszczonymi w leczeniu atopowego zapalenia skóry są upadacytynib (inhibitor JAK), dupilumab (przeciwciało monoklonalne przeciwko IL-4, IL-13) oraz crisaborole (inhibitor DPE-4).…”

Section: Leczenieunclassified

Chronic pruritus in atopic dermatitis – mechanisms and different ways of treatment, affect on quality of life

Sandra

MORAWSKI

Augustynowicz

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Pruritus in atopic dermatitis is one of the main symptoms of the disease and the one that causes a significant impact on quality of life. It is important to control itching because it’s not only an unplesant sense. Scratching topically deepen the dermatitis, damages the epidermal barrier causing additional infections possible and makes it harder to acheive a remission of the disease. It is also highly associated with stress and has an impact on mental health of the patient. In this article we present a summary of how pruritus affects the quality of life, mechanisms of pruritus and possible treatment. Materials and methods: Our work is based on the articles published in PubMed, medical books and websites. We were looking for the key words such as ‘stress and itch’, ‘pruritus treatment’, ‘chronic itch in atopic dermatitis’, ‘itch and quality of life’. Results: Patients with atopic dermatitis should come under miltidisciplinar treatment to acheive the best possible control of symptoms. This will result in higher quality of life and better mental health of the patient. Conclusions: There is a high need to develop new targeted medications as contemporary medicine knows a lot more about the mechanism of pruritus. Many new types of treatment are being studied and soon we may have more options to choose in systemic and topical therapy. We should also concetrate more on a mental side of the disease.

show abstract

“…Traditionally, treatment of AD has consisted of systemic drugs (cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil), topical ointments (corticosteroids, calcineurin inhibitors) and phototherapies (NB-UVB, UVA1, PUVA) 15 , 16 . More recently, administrations of more specific biological agents, e.g.…”

Section: Introductionmentioning

confidence: 99%

Identification of novel candidate genes and predicted miRNAs in atopic dermatitis patients by bioinformatic methods

Chen

Xin

Wang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common, chronic inflammatory dermatosis with relapsing eruptions. Our study used bioinformatics to find novel candidate differentially expressed genes (DEGs) and predicted miRNAs between AD patients and healthy controls. The Mesh term “atopic dermatitis” was retrieved to obtain DEGs in GEO datasets. DEGs between AD patients and healthy controls were analyzed using GEO2R. Overlapping DEGs between different datasets were obtained with use of Draw Venn software. GO and KEGG enrichment analyses were conducted by the use of DAVID. STRING and miRWalk were used to individually analyze PPI networks, interactions of candidate genes and predicted miRNAs. A total of 571 skin samples, as retrieved from 9 databases were assessed. There were 225 overlapping DEGs between lesioned skin samples of AD patients and that of healthy controls. Nineteen nodes and 160 edges were found in the largest PPI cluster, consisting of 17 up-regulated and 2 down-regulated nodes. Two KEGG pathways were identified, including the cell cycle (CCNB1, CHEK1, BUB1B, MCM5) and p53 (CCNB1, CHEK1, GTSE1) pathways. There were 56 nodes and 100 edges obtained in the miRNA-target gene network, with has-miR-17-5p targeted to 4 genes and has-miR-106b-5p targeted to 3 genes. While these findings will require further verification as achieved with experiments involving in vivo and in vitro modles, these results provided some initial insights into dysfunctional inflammatory and immune responses associated with AD. Such information offers the potential to develop novel therapeutic targets for use in preventing and treating AD.

show abstract

Phototherapy for atopic eczema

Abstract: Trusted evidence. Informed decisions. Better health.

Cited by 21 publications

References 151 publications

Phototherapy for atopic dermatitis: A survey of European practice

Phototherapy for atopic dermatitis: A survey of European practice

Chronic pruritus in atopic dermatitis – mechanisms and different ways of treatment, affect on quality of life

Identification of novel candidate genes and predicted miRNAs in atopic dermatitis patients by bioinformatic methods

Contact Info

Product

Resources

About